X

Trial Profile

Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
Indications Liver cancer
Focus Therapeutic Use

Most Recent Events

05 Jul 2024 Status changed from recruiting to active, no longer recruiting.
24 Jun 2023 Results (As of December 31, 2022, n=30) assessing the liver-related adverse events (AE)of atezolizumab (atezo) plus bevacizumab (bev) for uHCC with highHBV viral load presented at the European Association for the Study of the Liver Congress 2023
05 Apr 2023 Planned End Date changed from 30 Dec 2023 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com